Kringle Pharma (TSE:4884) Beta: 0.0579 (As of Aug. 11, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4884 Kringle Pharma Inc TSE:4884
50 GF Score
Price 円362.00
GF Value 円483.87
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Kringle Pharma Beta?

Kringle Pharma TSE:4884 +4.32% 50 Beta is 0.0579 as of Aug. 11, 2026. GuruFocus rates TSE:4884 with a GF Score™ of 50/100 and a GF Value™ of 円483.87 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-08-11), Kringle Pharma's Beta is 0.0579.


Kringle Pharma  (TSE:4884) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Kringle Pharma Beta Related Terms


Kringle Pharma Beta Historical Data

* Premium members only.

The historical data trend for Kringle Pharma's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kringle Pharma Beta Chart

Kringle Pharma Annual Data
Trend Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Beta
Get a 7-Day Free Trial 0.00 0.00 0.00 0.55 0.03

Kringle Pharma Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.41 0.26 0.03 0.04 0.08

TSE:4884 vs VRTX, REGN, RVMD: Beta Comparison

For the Biotechnology subindustry, Kringle Pharma's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kringle Pharma Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kringle Pharma's Beta distribution charts can be found below:

* The bar in red indicates where Kringle Pharma's Beta falls into.


TSE:4884
50GF Score
Kringle Pharma Inc TSE:4884
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kringle Pharma Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.0579 mean?
Kringle Pharma (TSE:4884) has a Beta of 0.0579 as of Aug. 11, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Kringle Pharma and its competitors.
Is Kringle Pharma's Beta too high?
Kringle Pharma's current Beta is 0.0579. Overall, Kringle Pharma has a GF Score™ of 50/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kringle Pharma's Beta compare to VRTX and REGN?
Kringle Pharma's Beta of 0.0579 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Kringle Pharma and its competitors. Kringle Pharma's current Beta is 0.0579. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kringle Pharma stock overvalued right now?
Based on GuruFocus' analysis, Kringle Pharma (TSE:4884) is currently considered Modestly Undervalued. The stock's GF Value™ is 円483.87, compared to a current price of 円362.00 — trading 25.2% below its estimated fair value. The current Beta is 0.0579. Kringle Pharma's overall GF Score™ is 50/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Kringle Pharma (TSE:4884), the current Beta is 0.0579 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kringle Pharma (TSE:4884) Overvalued in 2026?

Based on GuruFocus' analysis, Kringle Pharma stock appears to be undervalued. The current stock price of 円362.00 is trading 25.2% below its estimated GF Value™ of 円483.87. GuruFocus considers Kringle Pharma to be Modestly Undervalued.

Key valuation signals for TSE:4884:

  • Beta: 0.0579
  • GF Value™: 円483.87 vs. price of 円362.00 (25.2% below fair value)
  • GF Score™: 50/100 with 5 warning signs

No single metric tells the full story. See the TSE:4884 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Kringle Pharma Business Description

Address 7-7-15 Saito asagi, 207 Saito Bio-Incubator, Osaka Prefecture, Ibaraki, JPN, 567-0085
Kringle Pharma Inc is engaged in the research and development of HGF (hepatocyte growth factor) protein as a therapeutic agent for intractable diseases. The Company operates in a single segment, pharmaceutical development.
50GF Score

Get the complete analysis for TSE:4884

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円362.00
Price
円483.87
GF Value